Online inquiry

IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ6875MR)

This product GTTS-WQ6875MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CX3CL1 gene. The antibody can be applied in Crohn's disease (CD) research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 0
Species	Chimeric; Humanized
RefSeq	NM_002996.6
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	6376
UniProt ID	P78423

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6875MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ8561MR	IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	Hu5F9-G4
GTTS-WQ8408MR	IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	HS006
GTTS-WQ1550MR	IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	ACE-041
GTTS-WQ12917MR	IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	OTSA101-DTPA
GTTS-WQ261MR	IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	17-1A
GTTS-WQ19MR	IVTScrip™ mRNA-Anti-S, 2130(Cap 0, Pseudo-UTP, 120 nt-poly(A))	mRNA	2130
GTTS-WQ2504MR	IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	AMG 212
GTTS-WQ4401MR	IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	BMS-224818

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST